829 related articles for article (PubMed ID: 28335781)
21. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
[TBL] [Abstract][Full Text] [Related]
22. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
23. Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection.
Aspeslagh S; Nemčovič M; Pauwels N; Venken K; Wang J; Calenbergh SV; Zajonc DM; Elewaut D
J Immunol; 2013 Sep; 191(6):2916-25. PubMed ID: 23960235
[TBL] [Abstract][Full Text] [Related]
24. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice.
Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772
[TBL] [Abstract][Full Text] [Related]
25. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
26. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
27. An in silico approach for modelling T-helper polarizing iNKT cell agonists.
De Spiegeleer A; Wynendaele E; Vandekerckhove M; Stalmans S; Boucart M; Van Den Noortgate N; Venken K; Van Calenbergh S; Aspeslagh S; Elewaut D
PLoS One; 2014; 9(1):e87000. PubMed ID: 24498010
[TBL] [Abstract][Full Text] [Related]
28. α-Galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells.
Chuang YH; Wang TC; Jen HY; Yu AL; Chiang BL
J Immunol; 2011 Apr; 186(8):4687-92. PubMed ID: 21383248
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells.
Sullivan BA; Nagarajan NA; Wingender G; Wang J; Scott I; Tsuji M; Franck RW; Porcelli SA; Zajonc DM; Kronenberg M
J Immunol; 2010 Jan; 184(1):141-53. PubMed ID: 19949076
[TBL] [Abstract][Full Text] [Related]
30. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
[TBL] [Abstract][Full Text] [Related]
31. Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes.
Arora P; Kharkwal SS; Ng TW; Kunnath-Velayudhan S; Saini NK; Johndrow CT; Chang YT; Besra GS; Porcelli SA
Chem Phys Lipids; 2015 Oct; 191():75-83. PubMed ID: 26306469
[TBL] [Abstract][Full Text] [Related]
32. Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.
Denkberg G; Stronge VS; Zahavi E; Pittoni P; Oren R; Shepherd D; Salio M; McCarthy C; Illarionov PA; van der Merwe A; Besra GS; Dellabona P; Casorati G; Cerundolo V; Reiter Y
Eur J Immunol; 2008 Mar; 38(3):829-40. PubMed ID: 18253930
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
Berkers CR; Ovaa H
Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
[TBL] [Abstract][Full Text] [Related]
34. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide.
Sullivan BA; Kronenberg M
J Clin Invest; 2005 Sep; 115(9):2328-9. PubMed ID: 16138189
[TBL] [Abstract][Full Text] [Related]
35. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy.
Araki M; Miyake S; Yamamura T
Curr Med Chem; 2008; 15(23):2337-45. PubMed ID: 18855664
[TBL] [Abstract][Full Text] [Related]
36. iNKT-cell responses to glycolipids.
Parekh VV; Wilson MT; Van Kaer L
Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
[TBL] [Abstract][Full Text] [Related]
37. Natural killer T cell activation increases iNOS
Paul S; Chhatar S; Mishra A; Lal G
J Immunother Cancer; 2019 Aug; 7(1):208. PubMed ID: 31387637
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of acyl-chain- and galactose-6''-modified analogues of α-GalCer for NKT cell activation.
Hsieh MH; Hung JT; Liw YW; Lu YJ; Wong CH; Yu AL; Liang PH
Chembiochem; 2012 Jul; 13(11):1689-97. PubMed ID: 22730199
[TBL] [Abstract][Full Text] [Related]
39. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
40. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
Godó M; Sessler T; Hamar P
Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
